Review
Dermatology
L. Zhang, L. Guo, L. Wang, X. Jiang
Summary: JAK inhibitors are a promising treatment approach for plaque psoriasis and this study compared the efficacy and safety of different JAK inhibitors. Results showed that tofacitinib had the highest probability of achieving PASI75 and PGA response, and had a relatively good safety profile. This study confirmed the efficacy of JAK inhibitors in treating moderate-to-severe plaque psoriasis.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
(2022)
Review
Medicine, General & Internal
Robert Harrington, Patricia Harkins, Richard Conway
Summary: This article reviews the key findings of the most impactful cohort of studies and registry data since the ORAL Surveillance study and evaluates the role of JAKis in practice and how to determine the suitability of patients for JAKi use.
JOURNAL OF CLINICAL MEDICINE
(2023)
Review
Dermatology
Lu Zhang, Lian Wang, Xian Jiang
Summary: The study compared the efficacy of JAK inhibitors for AD treatment and found promising results, showing that JAK inhibitors had good treatment efficacy for AD patients, with upadacitinib and delgocitinib performing well among all included formulations.
DERMATOLOGIC THERAPY
(2021)
Article
Dermatology
Yue Xiao, Hongmei Xiang, Wei Li
Summary: This case report describes a successful treatment of a Chinese man with concurrent plaque psoriasis and bullous pemphigoid using the Janus kinase inhibitor Baricitinib. Significant improvement in skin lesions and pruritus was observed, and complete remission was achieved without any adverse effects at the 24-week follow-up.
DERMATOLOGIC THERAPY
(2022)
Article
Pharmacology & Pharmacy
Go Ishikawa, Chulwon Kwon, Yasutomo Fujii
Summary: We compared the pharmacologic properties of two Janus kinase (JAK) inhibitors, peficitinib and tofacitinib, in a rat model of adjuvant-induced arthritis. Results showed dose-dependent and significant attenuation of arthritis symptoms by both drugs, with peficitinib 10 mg/kg and tofacitinib 3 mg/kg demonstrating comparable efficacy. Both drugs achieved similar plasma concentration levels, suggesting comparable efficacy on arthritis-associated symptoms. However, peficitinib showed greater efficacy than tofacitinib on inflammation- and bone destruction-associated parameters. This might be due to the additional off-target effects of peficitinib in addition to JAK inhibition.
EUROPEAN JOURNAL OF PHARMACOLOGY
(2023)
Review
Immunology
Ching-Yi Chen, Wang-Chun Chen, Chi-Kuei Hsu, Chien-Ming Chao, Chih-Cheng Lai
Summary: JAK inhibitors can reduce the mortality rate and increase the recovery rate of COVID-19 patients, as well as shorten the recovery time. The use of JAK inhibitors also lowers the rate of patients needing invasive mechanical ventilation without increasing the risk of adverse events.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2021)
Article
Pharmacology & Pharmacy
Ziteng Wang, Eric Chun Yong Chan
Summary: Research evaluated dosing strategies of baricitinib and tofacitinib for COVID-19 treatment in elderly patients, showing that current dosage adjustments based on renal functions are broadly adequate for elderly populations, but may need to reduce the recommended dose of baricitinib in White older subjects.
CLINICAL PHARMACOLOGY & THERAPEUTICS
(2022)
Review
Chemistry, Medicinal
Ananyan Sampath, Aditya Banerjee, Shubham Atal, Ratinder Jhaj
Summary: This study assessed the role of baricitinib as a treatment for COVID-19 patients. A systematic literature search was conducted to find relevant clinical studies. The results showed that baricitinib, as an add-on to standard therapy, had favorable outcomes in hospitalized patients with moderate to severe COVID-19. Ongoing trials also support the safety and efficacy of this drug in COVID-19.
MEDICINAL RESEARCH REVIEWS
(2023)
Article
Medicine, General & Internal
Shu Li, Fen Li, Ni Mao, Jia Wang, Xi Xie
Summary: This study assessed the efficacy and safety of JAK inhibitors in the treatment of ankylosing spondylitis. The meta-analysis results showed that JAK inhibitors not only mitigated disease activity, but also significantly improved patients' physical function, emotional well-being, and social participation.
EUROPEAN JOURNAL OF INTERNAL MEDICINE
(2022)
Review
Rheumatology
J. J. Paik, G. Lubin, A. Gromatzky, P. N. Mudd Jr, M. P. Ponda, L. Christopher-Stine
Summary: Dermatomyositis is an inflammatory muscle disease that often involves skin, lungs, gastrointestinal system, joints, and heart. Steroids and intravenous immunoglobulin are currently used to treat DM, but more targeted approaches are needed. Blocking the JAK pathway to inhibit interferon signaling shows potential as a treatment option.
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY
(2023)
Review
Pharmacology & Pharmacy
Juqi Zhang, Wenhui Li, Mingli Gong, Yanlun Gu, Hanxu Zhang, Bingqi Dong, Qi Guo, Xiaocong Pang, Qian Xiang, Xu He, Yimin Cui
Summary: This study found that the use of Janus kinase (JAK) inhibitors in patients with immune-mediated inflammatory diseases may increase the risk of venous thrombosis (VTE), especially with high doses of tofacitinib. Compared to placebo or tumor necrosis factor (TNF) inhibitors, JAK inhibitors did not show a significant difference in VTE incidence. These findings are important for physicians considering the use of JAK inhibitors in patients with immune-mediated inflammatory diseases.
FRONTIERS IN PHARMACOLOGY
(2023)
Review
Dermatology
Huiying Wan, Haiping Jia, Tian Xia, Dingding Zhang
Summary: This study conducted a network meta-analysis to compare the efficacy and safety of three common oral JAK inhibitors, abrocitinib, baricitinib, and upadacitinib, for moderate-to-severe atopic dermatitis (AD). The results showed that all three treatments were effective, but upadacitinib 30 mg may be the optimal option in short-term studies, although it had a higher risk of treatment-emergent adverse events (TEAEs).
DERMATOLOGIC THERAPY
(2022)
Review
Pharmacology & Pharmacy
Qige Wei, Hui Wang, Jianglin Zhao, Zhongping Luo, Chufeng Wang, Chunmei Zhu, Na Su, Shengzhao Zhang
Summary: This article is a systematic review and network meta-analysis on the relationship between different JAK inhibitors used in patients with rheumatoid arthritis (RA) and cardiovascular risks. The study found that JAK inhibitors may not increase the risk of MACE, but may be associated with higher all-cause mortality compared to adalimumab, primarily due to the use of tofacitinib.
FRONTIERS IN PHARMACOLOGY
(2023)
Review
Oncology
Juuli Raivola, Teemu Haikarainen, Bobin George Abraham, Olli Silvennoinen
Summary: The JAK/STAT pathway is crucial for immune cell development and function, with mutations linked to hematological diseases like leukemia. Current therapeutic strategies target the pathway's aberrant activation, with FDA-approved JAK inhibitors showing promise in treating autoimmune diseases and blood cancers. However, there is a need for more effective JAK modulators to fully harness their potential in leukemia treatment.
Article
Gastroenterology & Hepatology
David T. Rubin, Irene Modesto, Severine Vermeire, Silvio Danese, Siew C. Ng, Kenneth K. Kwok, Nana Koram, Thomas Jones
Summary: The study analyzed post-marketing surveillance case safety reports for tofacitinib in patients with ulcerative colitis, showing that serious adverse events mainly included infections, gastrointestinal issues, and vascular disorders. Most reported adverse events were non-serious.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2022)